Abstract
The human Dkk-1 (hDkk-1) gene, a transcriptional target of the p53 tumor suppressor, encodes a powerful inhibitor of the Wnt signaling pathway and regulates the spatial patterning/morphogenesis of the mammalian central nervous system. We investigated the p53-related functions of the hDkk-1 gene by studying its response to DNA damage and its modulation of apoptosis in human glioma cells. Various chemotherapeutic and other agents that induce DNA adducts and compromise its integrity (1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU), cisplatin, H2O2 and UV rays) enhanced the expression of hDkk-1 significantly. The damage-induced increase in hDkk-1 mRNA levels occurred in many human tumor cell lines, irrespective of their p53 gene status. The human glioblastoma cell line, U87MG, which had undetectable hDkk-1 expression, was engineered to express moderate levels of the hDkk protein by stable transfection. The engineered cells did not show any morphological changes, but underwent marked apoptosis after ceramide treatment. Further, the DNA cross-linking drugs BCNU and cisplatin, but not the microtubule poison vincristine, induced significant cell death in U87MG/hDkk cells, and this was accompanied by altered Bcl-2/Bax expression and a reduction in the amount of telomere DNA as visualized by fluorescence in situ hybridization. These results show that hDkk-1 is a pro-apoptotic gene and suggest that it may play important roles in linking the oncogenic Wnt and p53 tumor suppressor pathways.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Abbreviations
- APC:
-
adenomatous polyposis coli
- BCNU:
-
1,3-bis(2-chloroethyl)-1-nitrosourea
- FISH:
-
fluorescence in situ hybridization
- GSK3:
-
glycogen synthase kinase 3
- hDkk-1:
-
human Dkk-1
References
Ausubel FM, Brent R, Kingston RE, Moore DD, Smith JA, Seidman JG, Struhl K (eds) . 1987 Current Protocols in Molecular Biology New York: Wiley Interscience
Barker N, Morin PJ, Clevers H . 2000 Adv. Cancer Res. 77: 1–24
Burger AM, Double JA, Newell DR . 1997 Eur. J. Cancer 33: 638–644
Burkhart BA, Alcorta DA, Chiao C, Isaacs JS, Barrett JC . 1999 Exp. Cell Res. 247: 168–175
Chen S, Guttridge DC, You Z, Zhang Z, Fribley A, Mayo MW, Kitajewski J, Wang C-Y . 2001 J. Cell Biol. 152: 87–96
Dale TC . 1998 Biochem. J. 329: 209–223
De Lange T . 1995 Telomere dynamics and genome instability in human cancer Telomeres Cold Spring Harbor, NY: Cold Spring Harbor Press pp 265–293
Deng Y, Wu X . 2000 Proc. Natl. Acad. Sci. USA 97: 12050–12055
Downing KH . 2000 Annu. Rev. Cell Dev. Biol. 16: 89–111
Fedi P, Bafico A, Nieto Soria A, Burgess WH, Miki T, Bottaro DP, Kraus MH, Aaronson SA . 1999 J. Biol. Chem. 274: 19465–19472
Finch PW, He X, Kelley MJ, Uren A, Schaudies RP, Popescu NC, Rudikoff S, Aaronson SA, Varmus HE, Rubin JS . 1997 Proc. Natl. Acad. Sci. USA 94: 6770–6775
Glinka A, Wu W, Delius H, Monaghan AP, Blumenstock C, Niehrs C . 1998 Nature 391: 357–362
Hannun YA . 1996 Science 274: 1855–1859
Hannun YA, Luberto C . 2000 Trends Cell Biol. 10: 73–80
Hart MJ, de los Santos R, Albert IN, Rubinfeld B, Polakis P . 1998 Curr. Biol. 8: 573–581
Hayashi S, Rubinfeld B, Souza B, Polakis P, Wieschaus E, Levine AJ . 1997 Proc. Natl. Acad. Sci. USA 94: 242–247
Henriksson M, Selivanova G, Lindstrom M, Wiman KG . 2001 Apoptosis 6: 133–137
Howe LR, Subbaramaiah K, Chung WJ, Dannenberg AJ, Brown AM . 1999 Cancer Res. 59: 1572–1577
Ishii K, Yang W-L, Cvijic ME, Kikuchi Y, Nagata I, Chin K-V . 2000 Exp. Cell Res. 255: 95–101
Ishibashi T, Lippard SJ . 1998 Proc. Natl. Acad. Sci. USA 95: 4219–4223
Israeli D, Tessler E, Haupt Y, Elkeles A, Wilder S, Amson R, Telerman A, Oren M . 1997 EMBO J. 16: 4384–4392
Jaiswal AS, Narayan S . 2001 J. Biol. Chem. 276: 18193–18199
Jayadev S, Liu B, Bielawska AE, Lee JY, Nazaire F, Pushkareva MY, Obeid LM, Hannun YA . 1995 J. Biol. Chem. 270: 2047–2052
Jimenez GS, Khan SH, Stommel JM, Wahl GM . 1999 Oncogene 18: 7656–7665
Johnson M, Dimitrov D, Vojta P, Barrett JC, Noda A, Pereira-Smith OM, Smith JR . 1994 Mol. Carcinog. 11: 59–64
Kanaya T, Kyo S, Hamada K, Takakura M, Kitagawa Y, Harada H, Inoue M . 2000 Clin. Cancer Res. 6: 1239–1247
Kazanskaya O, Glinka A, Niehrs C . 2000 Development 127: 4981–4992
Kruk PA, Rampino NJ, Bohr VA . 1995 Proc. Natl. Acad. Sci. USA 92: 258–262
Krupnik VE, Sharp JD, Jiang C, Robison K, Chickering TW, Amaravadi L, Brown DE, Guyot D, Mays G, Leiby K, Chang B, Duong T, Goodearl AD, Gearing DP, Sokol SY, McCarthy SA . 1999 Gene 238: 301–313
Leyns L, Bouwmester T, Kim SH, Piccolo S, De Robertis EM . 1997 Cell 88: 747–756
Mao B, Wu W, Li Y, Hoppe D, Stannek P, Glinka A, Niehrs C . 2001 Nature 411: 255–256
McGrew LL, Takemaru K, Bates R, Moon RT . 1999 Mech. Dev. 87: 21–32
Melkonyan HS, Chang WC, Shapiro JP, Mahadevappa M, Fitzpatrick PA, Kiefer MC, Tomei LD, Umansky SR . 1997 Proc. Natl. Acad. Sci. USA 94: 13636–13641
Miyagishi M, Fuji R, Hatta M, Yoshida E, Araya N, Nagafuchi A, Ishihara S, Nakajima T, Fukamizu A . 2000 J. Biol. Chem. 275: 35170–35175
Molenaar M, Destree O . 1999 Int. J. Dev. Biol. 43: 675–680
Moon RT, Brown JD, Yang-Snyder JA, Miller JR . 1997 Cell 88: 725–728
Multani AS, Chandra J, McConkey DJ, Sen S, Cabral TF, Pathak S . 1999 Oncol Res. 11: 455–460
Multani AS, Ozer M, Narayan S, Kumar V, Chandra J, McConkey D, Newman RA, Pathak S . 2000 Neoplasia 2: 339–345
Mukhopadhyay T, Multani AS, Roth JA, Pathak S . 1998 Oncogene 17: 901–906
Nagele RG, Velasco AQ, Anderson WJ, McMahon DJ, Thomson Z, Fazekas J, Wind K, Lee H-Y . 2001 J. Cell Sci. 114: 377–388
Naylor S, Smalley MJ, Robertson D, Gusterson BA, Edwards PA, Dale TC . 2000 J. Cell Sci. 113: 2129–2138
Nusse R . 2001 Nature 411: 255–256
Pathak S . 1976 J. Reprod. Med. 17: 25–28
Polakis P . 2000 Genes Dev. 14: 1837–1851
Robertson JD, Orrenius B . 2000 Crit. Rev. Toxicol. 30: 609–627
Roth W, Wild-Bode C, Platten M, Grimmel C, Melkonyan HS, Dichgans J, Weller M . 2000 Oncogene 19: 4210–4220
Sadot E, Geiger B, Oren M, Ben-Ze'ev A . 2001 Mol. Cell. Biol. 21: 6768–6781
Sakanaka C, Weiss JB, Williams LT . 1998 Proc. Natl. Acad. Sci. USA 95: 3020–3023
Sawada M, Nakashima S, Kiyono T, Nakagawa M, Yamada J, Yamakawa H, Banno Y, Shinoda J, Nishimura Y, Nozawa Y . 2001 Oncogene 20: 1368–1378
Schneider VA, Mercola M . 2001 Genes Dev. 15: 304–315
Scotting PJ, Thompson SL, Punt JA, Walker DA . 2000 Childs Nerv. Syst. 16: 261–267
Senchenkov A, Litvak DA, Cabot MC . 2001 J. Natl. Cancer Inst. 93: 347–357
Shimizu H, Julius MA, Giarre M, Zheng Z, Brown AM, Kitajewski J . 1997 Cell Growth Differ. 8: 1349–1358
Shutman M, Zhurinsky J, Simcha I, Albanese C, D'Amico M, Petsell RG, Ben-Ze'ev A . 1999 Proc. Natl. Acad. Sci. USA 96: 5522–5527
Srivenugopal KS, Ali-Osman F . 1997 Int. J. Oncol. 11: 1251–1256
Srivenugopal KS, Ali-Osman F . 1996 Proc. Amer. Assoc. Cancer Res. 37: p 5
Srivenugopal KS, Ali-Osman F . 1990 Biochem. Pharmacol. 40: 473–479
Tate G, Mitsuya T . 1999 J. Biochem. Mol. Biol. Biophys. 3: 239–242
Tetsu O, McCormick F . 1999 Nature 398: 422–426
Turenne GA, Price BD . 2001 BMC Cell Biol. 2: 12–16
Ueda Y, Hijikata M, Takagi S, Takada R, Takada S, Chiba T, Shimotohno K . 2001 Biochem. Biophys. Res. Commun. 283: 327–333
Van Meir EG, Kikuchi T, Tada M, Li H, Diserens AC, Wojcik BE, Huang HJ, Friedman T, de Tribolet N, Cavanee WK . 1994 Cancer Res. 54: 649–652
Wang J, Shou J, Chen X . 2000 Oncogene 19: 1843–1848
Wodarz A, Nusse R . 1998 Annu. Rev. Cell. Dev. Biol. 14: 59–88
Wolf V, Ke G, Dharmarajan AM, Bielke W, Artuso L, Saurer S, Friis R . 1997 FEBS Lett. 417: 385–389
Wong GT, Avin BJ, McMahon AP . 1994 Mol. Cell. Biol. 14: 6278–6286
Yoshimura S, Sakai H, Ohguchi K, Nakashima S, Banno Y, Nishimura Y, Sakai N, Nozawa Y . 1997 J. Neurochem. 69: 713–720
Zhou Z, Wang J, Han X, Zhou J, Linder S . 1998 Int. J. Cancer 78: 95–99
Zinda MJ, Vlahos CJ, Lai MT . 2001 Biochem. Biophys. Res. Commun. 280: 1107–1115
Acknowledgements
We gratefully acknowledge the supply of cell lines from Drs EG Van Meir, J Kitajevski, and J Smith. This work was supported by grants from the National Institutes of Health (CA-74321), Pediatric Brain Tumor Foundation of the United States, and the Association for Research of Childhood Cancer to KS Srivenugopal and a NIH grant (CA-79644) to F Ali-Osman.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Shou, J., Ali-Osman, F., Multani, A. et al. Human Dkk-1, a gene encoding a Wnt antagonist, responds to DNA damage and its overexpression sensitizes brain tumor cells to apoptosis following alkylation damage of DNA. Oncogene 21, 878–889 (2002). https://doi.org/10.1038/sj.onc.1205138
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1205138
Keywords
This article is cited by
-
Sema3C signaling is an alternative activator of the canonical WNT pathway in glioblastoma
Nature Communications (2023)
-
Gliosarcoma: distinct molecular pathways and genomic alterations identified by DNA copy number/SNP microarray analysis
Journal of Neuro-Oncology (2019)
-
Stromal fibroblast activation protein alpha promotes gastric cancer progression via epithelial-mesenchymal transition through Wnt/ β-catenin pathway
BMC Cancer (2018)
-
WNT signaling in glioblastoma and therapeutic opportunities
Laboratory Investigation (2016)
-
Chemotherapy-induced Dkk-1 expression by primary human mesenchymal stem cells is p53 dependent
Medical Oncology (2016)